MX2018013235A - Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida. - Google Patents
Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida.Info
- Publication number
- MX2018013235A MX2018013235A MX2018013235A MX2018013235A MX2018013235A MX 2018013235 A MX2018013235 A MX 2018013235A MX 2018013235 A MX2018013235 A MX 2018013235A MX 2018013235 A MX2018013235 A MX 2018013235A MX 2018013235 A MX2018013235 A MX 2018013235A
- Authority
- MX
- Mexico
- Prior art keywords
- hydroxypropan
- indazol
- trifluoromethyl
- pyridine
- ethyl
- Prior art date
Links
- OQAMEEFUUFJZRS-UHFFFAOYSA-N N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound OC(C)(C)C=1C(=CC2=CN(N=C2C=1)CCS(=O)(=O)C)NC(=O)C1=NC(=CC=C1)C(F)(F)F OQAMEEFUUFJZRS-UHFFFAOYSA-N 0.000 title 1
- -1 2-hydroxypropan-2-yl Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a formas cristalinas de N-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2H-indazol- 5-iI}-6-(trifluorometil)piridin-2-carboxamida, procesos para su preparación, composiciones farmacéuticas que las comprenden y su utilización en el control de trastornos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167652 | 2016-04-29 | ||
| PCT/EP2017/059767 WO2017186703A1 (en) | 2016-04-29 | 2017-04-25 | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013235A true MX2018013235A (es) | 2019-02-13 |
| MX383591B MX383591B (es) | 2025-03-14 |
Family
ID=55860769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013235A MX383591B (es) | 2016-04-29 | 2017-04-25 | Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida. |
| MX2018013234A MX380032B (es) | 2016-04-29 | 2017-04-25 | Sintesis de indazoles. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013234A MX380032B (es) | 2016-04-29 | 2017-04-25 | Sintesis de indazoles. |
Country Status (42)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| EP3423446B1 (de) | 2016-03-03 | 2020-09-16 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| US10501437B2 (en) | 2016-04-29 | 2019-12-10 | Bayer Pharma Aktiengesellschaft | Crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |
| US10759758B2 (en) * | 2016-04-29 | 2020-09-01 | Bayer Pharma Aktiengesellschaft | Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide |
| RU2743170C2 (ru) | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных |
| SG10202011653WA (en) | 2016-06-01 | 2020-12-30 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| PL3816164T3 (pl) | 2018-06-25 | 2024-08-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Związek izotiazolo[5,4-d]pirymidynowy jako inhibitor irak4 |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| CN110981903A (zh) * | 2019-11-28 | 2020-04-10 | 南京正济医药研究有限公司 | 一种艾日布林中间体化合物提高光学纯度的精制方法 |
| IL301396A (en) | 2020-09-30 | 2023-05-01 | Nobell Foods Inc | Recombinant milk proteins and food compositions comprising the same |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| CN114469979B (zh) * | 2021-12-15 | 2024-04-09 | 安徽贝克生物制药有限公司 | 一种核糖核苷类似物的药物组合物、吸入剂及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| KR20090005296A (ko) | 2006-02-10 | 2009-01-13 | 서미트 코포레이션 피엘씨 | 뒤시엔느 근이영양증의 치료 |
| EP2045253A4 (en) | 2006-06-29 | 2013-01-23 | Nissan Chemical Ind Ltd | alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient |
| BRPI0716549A2 (pt) | 2006-09-07 | 2013-09-24 | Biogen Idec Inc | moduladores de quinase associada de interleucina-1 |
| WO2011043479A1 (ja) | 2009-10-09 | 2011-04-14 | 田辺三菱製薬株式会社 | 脳梗塞治療薬 |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| LT2655357T (lt) | 2010-12-20 | 2016-10-10 | Merck Serono S.A. | Indazolilo triazolo dariniai, kaip irak inhibitoriai |
| WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| WO2015067782A1 (en) | 2013-11-08 | 2015-05-14 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9126984B2 (en) * | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| TWI667233B (zh) * | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| CA2935880A1 (en) | 2014-01-10 | 2015-07-16 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| US20180289685A1 (en) * | 2015-04-30 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| MX2018000512A (es) | 2015-07-15 | 2018-04-13 | Aurigene Discovery Tech Ltd | Compuestos de indazaol y azaindazol como inhibidores de la cinasa 4 asociada al receptor de interlucina 1 (irak-4). |
| EP3423446B1 (de) | 2016-03-03 | 2020-09-16 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| US10759758B2 (en) | 2016-04-29 | 2020-09-01 | Bayer Pharma Aktiengesellschaft | Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide |
| US10501437B2 (en) | 2016-04-29 | 2019-12-10 | Bayer Pharma Aktiengesellschaft | Crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |
| SG10202011653WA (en) | 2016-06-01 | 2020-12-30 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| RU2743170C2 (ru) | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных |
-
2017
- 2017-04-25 US US16/097,067 patent/US10759758B2/en active Active
- 2017-04-25 US US16/097,065 patent/US10501417B2/en active Active
- 2017-04-25 RS RS20231171A patent/RS64928B1/sr unknown
- 2017-04-25 PT PT177185584T patent/PT3448846T/pt unknown
- 2017-04-25 GE GEAP201714933A patent/GEP20217214B/en unknown
- 2017-04-25 CU CU2018000131A patent/CU20180131A7/es unknown
- 2017-04-25 EA EA201892415A patent/EA201892415A1/ru unknown
- 2017-04-25 EA EA201892430A patent/EA038035B1/ru unknown
- 2017-04-25 CN CN202110343286.3A patent/CN113185457A/zh active Pending
- 2017-04-25 ES ES17718560T patent/ES2966772T3/es active Active
- 2017-04-25 MA MA44759A patent/MA44759B1/fr unknown
- 2017-04-25 DK DK17718560.0T patent/DK3448848T3/da active
- 2017-04-25 HU HUE17718560A patent/HUE064389T2/hu unknown
- 2017-04-25 MX MX2018013235A patent/MX383591B/es unknown
- 2017-04-25 LT LTEP17718558.4T patent/LT3448846T/lt unknown
- 2017-04-25 SG SG11201808108XA patent/SG11201808108XA/en unknown
- 2017-04-25 IL IL262414A patent/IL262414B2/en unknown
- 2017-04-25 UA UAA201811516A patent/UA124103C2/uk unknown
- 2017-04-25 KR KR1020187030699A patent/KR102373017B1/ko not_active Expired - Fee Related
- 2017-04-25 FI FIEP17718560.0T patent/FI3448848T3/fi active
- 2017-04-25 CN CN201780026130.4A patent/CN109071489B/zh active Active
- 2017-04-25 DK DK17718558.4T patent/DK3448846T3/da active
- 2017-04-25 SI SI201731443T patent/SI3448848T1/sl unknown
- 2017-04-25 AU AU2017257211A patent/AU2017257211B2/en active Active
- 2017-04-25 MY MYPI2018703965A patent/MY190319A/en unknown
- 2017-04-25 WO PCT/EP2017/059744 patent/WO2017186689A1/en not_active Ceased
- 2017-04-25 WO PCT/EP2017/059767 patent/WO2017186703A1/en not_active Ceased
- 2017-04-25 UA UAA201811329A patent/UA123169C2/uk unknown
- 2017-04-25 MY MYPI2018703968A patent/MY187184A/en unknown
- 2017-04-25 SG SG11201808566WA patent/SG11201808566WA/en unknown
- 2017-04-25 JP JP2018556408A patent/JP6954924B2/ja active Active
- 2017-04-25 CA CA3022324A patent/CA3022324C/en active Active
- 2017-04-25 EP EP23189520.2A patent/EP4275755A3/en not_active Withdrawn
- 2017-04-25 HR HRP20231454TT patent/HRP20231454T1/hr unknown
- 2017-04-25 SI SI201730851T patent/SI3448846T1/sl unknown
- 2017-04-25 EP EP17718558.4A patent/EP3448846B1/en active Active
- 2017-04-25 JP JP2018556409A patent/JP7068188B2/ja active Active
- 2017-04-25 PE PE2018002251A patent/PE20190107A1/es unknown
- 2017-04-25 ES ES17718558T patent/ES2883298T3/es active Active
- 2017-04-25 MX MX2018013234A patent/MX380032B/es unknown
- 2017-04-25 HU HUE17718558A patent/HUE056460T2/hu unknown
- 2017-04-25 PL PL17718558T patent/PL3448846T3/pl unknown
- 2017-04-25 TN TNP/2018/000352A patent/TN2018000352A1/en unknown
- 2017-04-25 HR HRP20211072TT patent/HRP20211072T1/hr unknown
- 2017-04-25 PT PT177185600T patent/PT3448848T/pt unknown
- 2017-04-25 RS RS20210898A patent/RS62112B1/sr unknown
- 2017-04-25 EP EP23189176.3A patent/EP4275754A3/en not_active Ceased
- 2017-04-25 EP EP17718560.0A patent/EP3448848B1/en active Active
- 2017-04-25 LT LTEPPCT/EP2017/059767T patent/LT3448848T/lt unknown
- 2017-04-25 CN CN201780040919.5A patent/CN109415340B/zh active Active
- 2017-04-25 PL PL17718560.0T patent/PL3448848T3/pl unknown
- 2017-04-25 KR KR1020187030698A patent/KR102373220B1/ko not_active Expired - Fee Related
- 2017-04-25 AU AU2017256626A patent/AU2017256626B2/en active Active
- 2017-04-27 JO JOP/2017/0100A patent/JOP20170100B1/ar active
- 2017-04-27 JO JOP/2017/0099A patent/JOP20170099B1/ar active
- 2017-04-28 TW TW106114178A patent/TWI657084B/zh not_active IP Right Cessation
- 2017-04-28 UY UY0001037216A patent/UY37216A/es active IP Right Grant
- 2017-04-28 AR ARP170101088A patent/AR108245A1/es unknown
- 2017-04-28 UY UY0001037215A patent/UY37215A/es not_active Application Discontinuation
- 2017-04-28 TW TW106114180A patent/TWI649314B/zh active
-
2018
- 2018-10-26 PH PH12018502289A patent/PH12018502289B1/en unknown
- 2018-10-29 SV SV2018005775A patent/SV2018005775A/es unknown
- 2018-10-29 CL CL2018003088A patent/CL2018003088A1/es unknown
- 2018-10-29 DO DO2018000237A patent/DOP2018000237A/es unknown
- 2018-10-29 SA SA518400333A patent/SA518400333B1/ar unknown
- 2018-10-29 NI NI201800112A patent/NI201800112A/es unknown
- 2018-10-29 EC ECSENADI201881437A patent/ECSP18081437A/es unknown
- 2018-10-29 CL CL2018003087A patent/CL2018003087A1/es unknown
- 2018-10-29 IL IL262659A patent/IL262659B/en active IP Right Grant
- 2018-10-29 CO CONC2018/0011644A patent/CO2018011644A2/es unknown
- 2018-10-29 CO CONC2018/0011622A patent/CO2018011622A2/es unknown
- 2018-11-28 ZA ZA2018/08057A patent/ZA201808057B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013235A (es) | Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida. | |
| CO2018000113A2 (es) | Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina | |
| NI201800111A (es) | Formas cristalinas de n-[2-3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6- (trifluorometil)-piridin-2-carboxamida. | |
| DK3889145T3 (da) | 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme | |
| CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| EA201790275A1 (ru) | Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида | |
| DOP2016000161A (es) | Ureas asimétricas p- sustituidas y usos médicos de las mismas. | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2019000027A1 (es) | Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes. | |
| CL2018003109A1 (es) | Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. | |
| CL2015003431A1 (es) | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales | |
| EP3471645C0 (en) | LASER-ASSISTED MACHINING (LAM) OF NON-MONOLITHIC COMPOSITE BONE MATERIAL | |
| DK3519050T3 (da) | Sammensætninger til behandling af oftalmiske sygdomme | |
| DK3544630T3 (da) | Ernæringssammensætning med resistent stivelse som er egnet til behandling af neoplastiske sygdomme |